tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Nakamura K [Treatment of atopic dermatitis]. 2009 Arerugi pmid:19901507
Saeki H [Brief commentary on guidelines for the management of atopic dermatitis 2012 -the point of drug treatment]. 2013 Arerugi pmid:24608647
Ochiai T [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. 1992 Arerugi pmid:1374229
Teraki Y [Atopic dermatitis in pregnancy]. 2014 Arerugi pmid:24714179
Ebihara N [New strategy in the treatment of vernal keratoconjunctivitis by calcineurin inhibitor eye drops]. 2010 Arerugi pmid:21119297
Akutsu I et al. [Inhibitory effects of cyclosporin A and FK-506 on eosinophil chemotactic factor activity in culture supernatants of mononuclear cells from asthmatics]. 1992 Arerugi pmid:1280086
Yamamoto S [Guidelines for the management of atopic dermatitis 2006]. 2008 Arerugi pmid:19052504
Akutsu I et al. [Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]. 1992 Arerugi pmid:1377905
Hossain M et al. Effects of various drugs (staurosporine, herbimycin A, ketotifen, theophylline, FK506 and cyclosporin A) on eosinophil viability. 1994 Arerugi pmid:7520689
Takehara K [Treatment of juvenile atopic dermatitis]. 2010 Arerugi pmid:21212728
Akutsu I et al. [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. 1990 Arerugi pmid:1705791
Müller EG et al. Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. 2017 Arq Bras Oftalmol pmid:28832739
Liendo VL et al. Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. Arq Bras Oftalmol pmid:28954018
Zulim LFDC et al. Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. Arq Bras Oftalmol pmid:29995121
Carvalho CS et al. [Fibroblasts from recurrent pterygium and normal Tenon's capsule exposed to tacrolimus (FK-506)]. 2007 Mar-Apr Arq Bras Oftalmol pmid:17589693
Lasa J and Olivera P EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arq Gastroenterol pmid:28327826
Long C et al. Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. 2007 Arterioscler. Thromb. Vasc. Biol. pmid:17478757
Ikezoe T et al. Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. 2012 Arterioscler. Thromb. Vasc. Biol. pmid:22796578
Murakami R et al. Cyclosporin A enhances interleukin-8 expression by inducing activator protein-1 in human aortic smooth muscle cells. 2003 Arterioscler. Thromb. Vasc. Biol. pmid:12958044
Vindis C et al. Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-induced apoptosis. 2005 Arterioscler. Thromb. Vasc. Biol. pmid:15618541
Migita K et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. 2015 Arthritis Res. Ther. pmid:26036592
Choe JY et al. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. 2013 Arthritis Res. Ther. pmid:23406906
van der Windt AE et al. Inhibiting calcineurin activity under physiologic tonicity elevates anabolic but suppresses catabolic chondrocyte markers. 2012 Arthritis Rheum. pmid:22231955
Suzuki N et al. In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behçet's disease. 1997 Arthritis Rheum. pmid:9182928
de Paulis A et al. Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. 1997 Arthritis Rheum. pmid:9082935
Cho ML et al. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes. 2002 Arthritis Rheum. pmid:11817607
Kremer JM et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. 2003 Arthritis Rheum. pmid:14558080
Asano Y et al. Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts. 2005 Arthritis Rheum. pmid:15818662
Wilkes MR et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. 2005 Arthritis Rheum. pmid:16052580
Stone JH et al. Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. 1998 Arthritis Rheum. pmid:9704643
Yocum DE et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. 2003 Arthritis Rheum. pmid:14673984
Furst DE et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. 2002 Arthritis Rheum. pmid:12209503
Cho ML et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. 2002 Arthritis Rheum. pmid:12115224
Parker CT and Rennie T Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al. 2004 Arthritis Rheum. pmid:15457479
Haisheng H et al. Assessment of nerve regeneration across nerve allografts treated with tacrolimus. 2008 Artif Cells Blood Substit Immobil Biotechnol pmid:18925465
Dawson S et al. UCLA liver transplantation: analysis of immunological factors affecting outcome. 1996 Artif Organs pmid:8896726
Kashu Y et al. Prolongation of rat liver graft survival by splenectomy combined with low dose FK506 therapy. 1996 Artif Organs pmid:8896731
Ohshima S et al. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors. 1996 Artif Organs pmid:8896734
Wada Y et al. BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. 1996 Artif Organs pmid:8853794
Imanishi Y et al. Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation. 2011 Arzneimittelforschung pmid:21528645
Takayama T et al. Effects of the novel and potent lymphocyte-specific protein tyrosine kinase inhibitor TKM0150 on mixed lymphocyte reaction and contact hypersensitivity in mice. 2010 Arzneimittelforschung pmid:20533766
Lainesse A et al. Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. 2008 Arzneimittelforschung pmid:18589558
Haehner T et al. Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system. 2004 Arzneimittelforschung pmid:14979613
Marcelín-Jiménez G et al. Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. 2007 Arzneimittelforschung pmid:18074760
Iwasaki K et al. Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. 1992 Arzneimittelforschung pmid:1379812
Cacciarelli TV et al. Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. 1994 Oct-Dec ASAIO J. pmid:7532042
Tsubo T et al. Elimination of FK-506 by continuous hemodiafiltration in a liver transplant patient. 1997 Jul-Aug ASAIO J. pmid:9242954
Ogita K et al. Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report. 2003 Asian J Surg pmid:14530108
Li T et al. Effect of FK506 nanospheres on regeneration of allogeneic nerve after transplant. 2014 Asian Pac J Trop Med pmid:25066398
Dai YJ et al. Effect of pharmacological intervention on MIP-1α, MIP-1β and MCP-1 expression in patients with psoriasis vulgaris. 2014 Asian Pac J Trop Med pmid:25063291
Yasukochi Y et al. Reduction of serum TARC levels in atopic dermatitis by topical anti-inflammatory treatments. 2014 Asian Pac. J. Allergy Immunol. pmid:25268342
Labcharoenwongs P et al. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. 2012 Asian Pac. J. Allergy Immunol. pmid:23156846
Manuyakorn W et al. In vitro cytokine changes after pediatric liver transplantation. 2015 Asian Pac. J. Allergy Immunol. pmid:25840634
Clark K et al. Oxidative Stress Induces Disruption of the Axon Initial Segment. ASN Neuro pmid:29228786
Riba Torrecillas D et al. [Use of topical tacrolimus and its side-effects]. 2005 Aten Primaria pmid:15946616
Ichimaru N et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. 2001 Atherosclerosis pmid:11583721
Hamada N et al. Tacrolimus-eluting stent inhibits neointimal hyperplasia via calcineurin/NFAT signaling in porcine coronary artery model. 2010 Atherosclerosis pmid:19682688
Matsumoto T et al. Influence of FK506 on experimental atherosclerosis in cholesterol-fed rabbits. 1998 Atherosclerosis pmid:9699896
Grillo E et al. Necrobiosis lipoidica. 2014 Aust Fam Physician pmid:24600675
Grillo E et al. Skin rash associated with limb weakness. 2012 Aust Fam Physician pmid:23210105
Cooley HM et al. Resolution of pyoderma gangrenosum using tacolimus (FK-506) 1996 Aust N Z J Med pmid:8744629
Chung TH et al. Topical tacrolimus (FK506) for the treatment of feline idiopathic facial dermatitis. 2009 Aust. Vet. J. pmid:19796164
Dall'Olio E et al. Erosive pustular dermatosis of the leg: long-term control with topical tacrolimus. 2011 Australas. J. Dermatol. pmid:21332681
Shamsudin N et al. Objective assessment of vitiligo with a computerised digital imaging analysis system. 2015 Australas. J. Dermatol. pmid:25367709
Dar NR and Rao SU Facial lichen nitidus actinicus. 2012 Australas. J. Dermatol. pmid:22571575
Milcic D and Nikolic M Clinical effects of topical pimecrolimus in a patient with Fox-Fordyce disease. 2012 Australas. J. Dermatol. pmid:22571582
Lee FJ et al. Poor efficacy of oral tacrolimus in the treatment of severe generalized atopic eczema in adults: a small retrospective case series. 2012 Australas. J. Dermatol. pmid:23157781
Zirbs M et al. Demodicidosis associated with psoriasis therapy--two case reports. 2013 Australas. J. Dermatol. pmid:23905976
Patterson C and Coutts I Granuloma faciale successfully treated with topical tacrolimus. 2009 Australas. J. Dermatol. pmid:19659988
Cassis TB and Callen JP Bupropion-induced subacute cutaneous lupus erythematosus. 2005 Australas. J. Dermatol. pmid:16197429
Wilson LM and Reid CM Molluscum contagiosum in atopic dermatitis treated with 0.1% tacrolimus ointment. 2004 Australas. J. Dermatol. pmid:15250900
Christophers E Psoriasis: mechanisms and entry points for possible therapeutic interventions. 1996 Australas. J. Dermatol. pmid:8713012
Pirmez R et al. Acne keloidalis nuchae in renal transplant patients receiving tacrolimus and sirolimus. 2016 Australas. J. Dermatol. pmid:27124649
Starritt E and Lee S Erythroplasia of Queyrat of the glans penis on a background of Zoon's plasma cell balanitis. 2008 Australas. J. Dermatol. pmid:18412812
Black M and Marshman G Dermatomyositis and pemphigus vulgaris: association or coincidence? 2011 Australas. J. Dermatol. pmid:21605086
Hannah J et al. Tacrolimus use in lupus nephritis: A systematic review and meta-analysis. 2016 Autoimmun Rev pmid:26427983
Shinkura N et al. Autoantibodies to FK506 binding protein 12 (FKBP12) in autoimmune diseases. 1999 Autoimmunity pmid:10433096
Maalej A et al. Evidence of association between FKBP1B and thyroid autoimmune disorders in a large Tunisian family. 2004 Autoimmunity pmid:15497458
Thomson AW et al. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. 1993 Autoimmunity pmid:7505632
Lemster B et al. Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. 1994 Autoimmunity pmid:7539635
Thomson AW and Starzl TE FK 506 and autoimmune disease: perspective and prospects. 1992 Autoimmunity pmid:1382646
Mochizuki M and Kawashima H Effects of FK506, 15-deoxyspergualin, and cyclosporine on experimental autoimmune uveoretinitis in the rat. 1990 Autoimmunity pmid:1717007
Ni M et al. FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. 1990 Autoimmunity pmid:1717008
Matsumura C et al. Differential effects of FK506 and cyclosporin A on catecholamine release from bovine adrenal chromaffin cells. 2004 Auton Autacoid Pharmacol pmid:15541012
Nakagaki T et al. FK506 reduces abnormal prion protein through the activation of autolysosomal degradation and prolongs survival in prion-infected mice. 2013 Autophagy pmid:23800841
Gates T Atopic dermatitis: diagnosis, treatment, and aeromedical implications. 2007 Aviat Space Environ Med pmid:17225479
Ekici Günay N et al. Administration of Extract (EGb761) Alone and in Combination with FK506 Promotes Liver Regeneration in a Rat Model of Partial Hepatectomy. 2018 Balkan Med J pmid:29553465
Kise H et al. Cardiac and haemodynamic effects of tacrolimus in the halothane-anaesthetized dog. 2010 Basic Clin. Pharmacol. Toxicol. pmid:19912168
Zhang H et al. Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling. 2018 Basic Clin. Pharmacol. Toxicol. pmid:28945011
Han N et al. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. 2014 Basic Clin. Pharmacol. Toxicol. pmid:24238261
Huang F et al. Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study. 2018 Basic Clin. Pharmacol. Toxicol. pmid:29427400
Quteineh L et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. 2008 Basic Clin. Pharmacol. Toxicol. pmid:19067682
Kagaya H et al. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation. 2010 Basic Clin. Pharmacol. Toxicol. pmid:20136638
Kim IW et al. Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients. 2012 Basic Clin. Pharmacol. Toxicol. pmid:22469198
Panahi Y et al. Comparison of clinical efficacy of topical pimecrolimus with betamethasone in chronic skin lesions due to sulfur mustard exposure: a randomized, investigator-blind study. 2009 Basic Clin. Pharmacol. Toxicol. pmid:19143752
Velickovic-Radovanovic RM et al. Clinical pharmacokinetics of tacrolimus after the first oral administration in renal transplant recipients on triple immunosuppressive therapy. 2010 Basic Clin. Pharmacol. Toxicol. pmid:20102364
Hisamura F et al. Protective effect of green tea extract and tea polyphenols against FK506-induced cytotoxicity in renal cells. 2006 Basic Clin. Pharmacol. Toxicol. pmid:16445594
Hu R et al. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation. 2018 Basic Clin. Pharmacol. Toxicol. pmid:29603629
Cumming DV et al. Pharmacological preconditioning of primary rat cardiac myocytes by FK506. 1996 Sep-Oct Basic Res. Cardiol. pmid:8922254
Ikeda Y et al. Activation of ERK and suppression of calcineurin are interacting mechanisms of cardioprotection afforded by delta-opioid receptor activation. 2006 Basic Res. Cardiol. pmid:16619106